NCT01629225

GRK4 Polymorphisms Blood Pressure Response to Candesartan

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Third Military Medical University · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Detailed description

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Candesartan	To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension

Timeline

• Start date: 2013-07-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2012-06-27
• Last updated: 2014-11-18

Locations

1 site across 1 country: China